Related Experiment Video
Updated: May 13, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia
Judith A Siuciak1, Christine A Strick
1CNS Discovery, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
Abstract:
Phosphodiesterase 10A (PDE10A) is a recently identified member of the cyclic nucleotide phosphodiesterase family. PDE10A is notable in that it has a relatively restricted distribution: PDE10A mRNA and protein are expressed primarily in the dopaminoreceptive medium spiny neurons of the striatum. Potent and selective PDE10A inhibitors have recently been described in the scientific literature and their in vivo effects suggest the potential uses of PDE10A inhibitors in CNS disorders, particularly schizophrenia. This article provides a brief overview of the presently available scientific literature as well as recent meeting presentations.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antipsychotic Drugs: Typical and Atypical Agents
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...

